TAXUS Stent Breaking News

Your TAXUS Stent Lawyers provide the following articles are about Taxus-Stents and other commentary and information from news sources across the country and around the world. If you have suffered due to a TAXUS Stent, recieve a free case evaluation by filling out this simple form.

Safety of Neck Stents Debated

While safety concerns regarding drug-coated heart stents rage on, thousands of doctors at a recent annual meeting in Washington who do that procedure are also on the defensive for their work with neck stents. Some studies have found a higher rate of strokes and deaths among patients who receive neck stents.

A recent report published in the New England Journal of Medicine told of a trial in France in which 9.6 of patients died or suffered strokes within 30 days of having neck stents implanted, compared to just 3.9 percent of those who underwent surgery.

Medtronic says it will fix drug-pump catheter flaws

Medtronic Inc. said Tuesday it will have a plan to correct problems with two of its drug-pump catheters this week after the U.S. Food and Drug Administration slapped its most serious recall designation on the devices.

In July, Medtronic took 934 drug-pump catheters off the market after receiving 22 reports of catheter tips dislodging in patients' spines. Federal regulators on Friday designated the action a Class I recall because the dislodgement of the tip could result in the risk of infection or other serious health problems.

Medtronic recalled all unused Model 8731 intrathecal tip catheters and a related Model 8598 kit made on or before August 2004.

Boston Scientific Stent Problems Persisted

July 13, 2005 (businessweek.com)

ET Doctors continued reporting surgical problems with a heart stent made by Boston Scientific Corp. even after the company recalled nearly 100,000 of the devices and fixed a manufacturing flaw, according to a published report.

Angiotech Gets Favorable Patent Decision

January 24, 2005 (www.forbes.com)

In November, Angiotech entered an exclusive license to supply medical device maker Boston Scientific Corp. with the cancer drug paclitaxel to coat the Taxus stent. Taxus paclitaxel-coated stents accounted for $640 million of Boston Scientific's third-quarter coronary stent revenue of $686 million. Under the agreement, Angiotech gets royalties on Taxus sales.

Don't walk in my shoes

January 24, 2005 (www.startribune.com)

The Natick, Mass.-based company announced the one millionth implantation of its Taxus drug-coated heart stent -- a blockbuster device that raked in an estimated $2.1 billion in sales last year. And the next-generation Taxus Liberté stent was launched in 18 countries, on track for a mid-2006 U.S. introduction. Taxus is a subject dear to LaViolette, a former president of the company's Maple Grove-based cardiovascular business.

Angiotech Says Regulators Maintain Stent Patents

January 24, 2005 (www.metronews.ca)

Vancouver, British Columbia-based Angiotech, which makes drug coatings for Boston Scientific's coronary stents -- small devices used to prop open arteries -- said the European Patent Office decision reaffirmed its patent protection in Europe.

For additional information about our TAXUS Stent lawyers and a complimentary consultation, speak to a Client Relations representative at Weitz & Luxenberg today. Please fill out this simple form, call toll free 1 (800) 476-6070 or e-mail us at Clientrelations@weitzlux.com.

Weitz & Luxenberg is no longer accepting Taxus Stent cases.

see also:

Bare Metal Stent Recall Class 1 Recall: Boston Scientific Express2TM (bare metal) Coronary Stent
Taxus Stent Recall: Boston Scientific Class 1 bare metal recall

Breaking News TAXUS Stent Resources: TAXUS Stent Breaking News
Your TAXUS Stent Lawyers provide Breaking News about Taxus-Stents

News & Warnings TAXUS Stent research resources
You can use this section to do research about the TAXUS stent recall from sources such as the FDA